



\* Individuals with diabetes treated 74% by an average of 48%, further improvement was observed following the treatment period

\* 87% of individuals with hypertension lowered blood pressure, systolic BP reduced by an average of 11 mmHg

Totally, at the annual meeting of the American College of Lifestyle Medicine, Drs. David Katz, Chief Science Officer, and Mark Brenner, Head of Health, presented clinical trial results demonstrating the effectiveness of our digital therapeutic in treating diabetes and hypertension.

Digital Therapeutics are an emerging form of medicine that use software to help individuals actively manage chronic conditions. In a study published earlier this year, our digital behavioral intervention demonstrated effectiveness in lowering blood sugar among individuals with type 2 diabetes. After 12 weeks of treatment, average HbA1c was reduced 0.8%, and continued to improve after the treatment period to 1.12%. Results of the study were peer-reviewed and published earlier this year.

Our most recent study among individuals with hypertension demonstrated an average reduction in systolic blood pressure of 11 mmHg, more than twice the level of clinical significance. Among those with more severe hypertension (blood pressure > 160/90), 85% reduced blood pressure a clinically meaningful amount and the average systolic reduction was 17.8 mmHg. The complete study will be published later this year.

Our approach in chronic diseases and our digital therapeutics is creating and preventing diseases that are preventable, curable and caused by the same driver: bad behaviors," said Kevin Appelhans, Better's Co-founder and CEO.



David Katz, MD, Chief Science Officer and Mark Brenner, MD, Head of Health